News

ADX71149 has been discovered under the collaboration between Addex and Ortho-McNeil-Janssen Pharmaceuticals. As per the terms of the agreement, Addex is entitled to receive up to EUR112m in

Lucentis, a vascular endothelial growth factor (VEGF) inhibitor, was first approved by the US Food and Drug Administration for the treatment of neovascular (wet) age-related macular degeneration (AMD)

As the primary objective of the trial, Versartis will assess the safety and tolerability of a single subcutaneous dose of VRS-317 in the trial. The company expects to

The new subsidiary will be engaged on marketing and selling Astellas‘ global products like Omnic and OmnicOCAS as a tretamnet for functional symptoms of benign prostatic hyperplasia. Additionally,

Rockwell Medical is a biopharmaceutical company that offers products and services initially targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia. The company is

In a pivotal randomized, double-blind Phase 3 study, the drug has shown improvement in overall survival based on results. In the trial, the median overall survival was 10

The company has posted loss from operations of $7.03m, compared to $14.15m for the comparable period in 2009. For the full year ended 31 December 2010, the company

Xyzal, an antihistamine, is a prescription medication indicated for the symptoms of year round allergies, as well as a treatment for chronic hives and rashes of unknown cause

The primary endpoint of the trial is to determine the safety, tolerability and pharmacokinetics of the drug, although the design allows the collection of efficacy data as well.